Clinical TrialsMedicare | Clinical TrialsPrivate Insurance | Medicare Payment FDA | Cancer Research | Stem Cell Research |
||||
CLC
Urges Senate Passage of Stem Cell Research Enhancement Act April 10, 2007 The undersigned organizations dedicated to advocacy for people with cancer write to endorse S. 5, the Stem Cell Research Enhancement Act. Research leaders agree that the stem cell lines that are eligible for federal funding under the Bush Administration policy are inadequate for research on cancer and other serious and life-threatening illnesses. In recent testimony before the Senate Labor, Health and Human Services, and Education Appropriations Subcommittee, National Institutes of Health Director Elias Zerhouni urged a change in policy to provide scientists access to more cell lines. It is time to permit federal funding on stem cell lines that are derived from excess embryos according to ethical principles, including informed consent by donors. The Stem Cell Research Enhancement Act establishes appropriate standards for the expansion of federal funding of stem cell research. As advocates for cancer survivors, we strongly urge you to support this legislation that will allow stem cell research to move forward. Although other stem cell measures will be considered by the Senate when it debates the Stem Cell Research Enhancement Act, those measures do not address the pressing need for additional embryonic stem cell lines necessary to advance this research. The Stem Cell Research Enhancement Act represents an important step toward wider federal support of embryonic stem cell research. We urge you to vote for this bill. Sincerely, Cancer Leadership
Council Back to Stem Cell Research Index About CLC | What's New | Policy
Issues | Participants' Login Copyright
© 2001-2002 Cancer Leadership Council. All rights reserved. |